• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?

    6/16/24 2:25:10 PM ET
    $ACLS
    $CLSK
    $ENVX
    $ESI
    Industrial Machinery/Components
    Technology
    Finance: Consumer Services
    Finance
    Get the next $ACLS alert in real time by email

    These mid-cap stocks were the best performers in the last week. Are they in your portfolio?

    1. Avidity Biosciences, Inc. (NASDAQ:RNA) shares jumped 50.15% following the announcement that the Phase 1/2 trial data for muscle disorder therapy yielded positive results.
    2. Iris Energy Limited (NASDAQ:IREN) shares surged 24.31% after Cantor Fitzgerald assumed an Overweight rating on the stock and announced a $23 price target.
    3. Hims & Hers Health, Inc. (NYSE:HIMS) shares rose 15.29%.
    4. John Wiley & Sons, Inc. (NYSE:WLY) shares rose 14.07%  after the company reported Q4 adjusted EPS and sales that beat estimates.
    5. Element Solutions Inc. (NYSE:ESI) shares grew 13.46%  after the company raised Q2 and FY24 guidance. Mizuho and BMO Capital also raised their price forecasts for the stock.
    6. CleanSpark, Inc. (NASDAQ:CLSK) shares gained 13.31% amid strength in Bitcoin following softer-than-expected May CPI figures.
    7. Enovix Corporation (NASDAQ:ENVX) stock price escalated 12.97% as shares of several industrial companies gained amid overall market strength following positive inflation data.
    8. Axcelis Technologies, Inc. (NASDAQ:ACLS) shares advanced 12.70% last week. Semiconductor stocks gained on softer-than-expected CPI figures, which lifted stocks on Wednesday, while AI optimism also continues to boost the sector.
    9. Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock price upped 12.08%.
    10. Korn Ferry (NYSE:KFY) shares increased 8.13% following the company’s Q4 earnings. A couple of analysts raised the price forecasts on the stock.

      Also Read: Celsius And PayPal Were Among The 10 Biggest Large Cap Losers Last Week (June 9-June 15): Are These In Your Portfolio?

      Image: 15958319 from Pixabay

      Get the next $ACLS alert in real time by email

      Crush Q1 2026 with the Best AI Superconnector

      Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

      AI-Powered Inbox
      Context-aware email replies
      Strategic Decision Support
      Get Started with Standout.work

      Recent Analyst Ratings for
      $ACLS
      $CLSK
      $ENVX
      $ESI

      CompanyDatePrice TargetRatingAnalyst
      Enovix Corporation
      $ENVX
      3/12/2026$6.00Neutral
      BofA Securities
      Atrium Therapeutics Inc.
      $RNA
      3/11/2026$25.00Overweight
      Wells Fargo
      Hims & Hers Health Inc.
      $HIMS
      3/10/2026$24.00Sell → Neutral
      Citigroup
      Hims & Hers Health Inc.
      $HIMS
      3/10/2026$23.00Underperform → Neutral
      BofA Securities
      Hims & Hers Health Inc.
      $HIMS
      3/9/2026$30.00Hold → Buy
      Needham
      Intellia Therapeutics Inc.
      $NTLA
      3/2/2026Mkt Perform → Outperform
      William Blair
      Enovix Corporation
      $ENVX
      2/26/2026$15.00 → $7.50Hold
      TD Cowen
      Hims & Hers Health Inc.
      $HIMS
      2/24/2026Buy → Neutral
      BTIG Research
      More analyst ratings

      $ACLS
      $CLSK
      $ENVX
      $ESI
      SEC Filings

      View All

      SEC Form DEF 14A filed by Axcelis Technologies Inc.

      DEF 14A - AXCELIS TECHNOLOGIES INC (0001113232) (Filer)

      3/31/26 7:28:35 AM ET
      $ACLS
      Industrial Machinery/Components
      Technology

      Amendment: SEC Form SCHEDULE 13G/A filed by Korn Ferry

      SCHEDULE 13G/A - KORN FERRY (0000056679) (Subject)

      3/27/26 10:19:35 AM ET
      $KFY
      Diversified Commercial Services
      Consumer Discretionary

      Amendment: SEC Form SCHEDULE 13G/A filed by John Wiley & Sons Inc.

      SCHEDULE 13G/A - JOHN WILEY & SONS, INC. (0000107140) (Subject)

      3/27/26 10:17:07 AM ET
      $WLY
      Books
      Consumer Discretionary

      $ACLS
      $CLSK
      $ENVX
      $ESI
      Insider Trading

      Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

      View All

      SEC Form 4 filed by Cavaleri Amanda

      4 - CLEANSPARK, INC. (0000827876) (Issuer)

      4/2/26 9:03:02 PM ET
      $CLSK
      Finance: Consumer Services
      Finance

      SEC Form 4 filed by Beynon Roger Paul

      4 - CLEANSPARK, INC. (0000827876) (Issuer)

      4/2/26 9:02:03 PM ET
      $CLSK
      Finance: Consumer Services
      Finance

      SEC Form 4 filed by Wood Thomas Leigh

      4 - CLEANSPARK, INC. (0000827876) (Issuer)

      4/2/26 9:01:03 PM ET
      $CLSK
      Finance: Consumer Services
      Finance

      $ACLS
      $CLSK
      $ENVX
      $ESI
      Analyst Ratings

      Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

      View All

      BofA Securities initiated coverage on Enovix with a new price target

      BofA Securities initiated coverage of Enovix with a rating of Neutral and set a new price target of $6.00

      3/12/26 8:51:29 AM ET
      $ENVX
      Industrial Machinery/Components
      Miscellaneous

      Wells Fargo initiated coverage on Atrium Therapeutics with a new price target

      Wells Fargo initiated coverage of Atrium Therapeutics with a rating of Overweight and set a new price target of $25.00

      3/11/26 8:36:38 AM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

      Hims & Hers Health upgraded by Citigroup with a new price target

      Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

      3/10/26 8:37:35 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care

      $ACLS
      $CLSK
      $ENVX
      $ESI
      Insider Purchases

      Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

      View All

      Director Cohen Fred E bought $1,402,500 worth of shares (150,000 units at $9.35), increasing direct ownership by 261% to 207,453 units (SEC Form 4)

      4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

      1/7/26 4:05:06 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

      Director Chase William J bought $1,003,000 worth of shares (100,000 units at $10.03), increasing direct ownership by 288% to 134,693 units (SEC Form 4)

      4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

      8/22/25 4:30:14 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

      Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      11/14/24 4:57:45 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

      $ACLS
      $CLSK
      $ENVX
      $ESI
      Press Releases

      Fastest customizable press release news feed in the world

      View All

      Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on April 1, 2026, it awarded inducement grants to 13 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 67,150 shares of Intellia's common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee's continued service as an employee of, o

      4/3/26 4:05:00 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

      Axcelis Announces SBTi Approval of Science-Based Greenhouse Gas Emissions Reduction Targets

      BEVERLY, Mass., March 30, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, is pleased to announce the approval of its greenhouse gas (GHG) emissions reduction targets by the Science Based Targets initiative (SBTi). The SBTi is a corporate climate action organization that enables companies worldwide to play their part in combating the climate crisis. Axcelis has committed to achieve net-zero GHG emissions across the value chain by 2050. The company has been granted approval fro

      3/30/26 8:00:00 AM ET
      $ACLS
      Industrial Machinery/Components
      Technology

      Novo Nordisk's FDA-Approved GLP-1s Now Available With Hims & Hers

      Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill Hims & Hers Health, Inc. (NYSE:HIMS) today announced that a broad assortment of Novo Nordisk's FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access FDA-approved GLP-1 medications which are now available at more affordable prices, with more doses and delivery methods. This expansion makes Hims & Hers the largest global consumer health platform for af

      3/26/26 12:00:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

      $ACLS
      $CLSK
      $ENVX
      $ESI
      Leadership Updates

      Live Leadership Updates

      View All

      Element Solutions Inc Announces Board Leadership Transition

      Element Solutions Inc (NYSE:ESI) ("Element Solutions" or the "Company"), a global and diversified specialty chemicals technology company, today announced that Sir Martin E. Franklin, Executive Chairman of the Board, plans to step down from the Board and will not seek re-election at the upcoming 2026 Annual Meeting of Stockholders. Ian G.H. Ashken, a founding Board director since 2013 and Chair of the Board's Nominating and Policies Committee, has been appointed Non-Executive Chairman of the Board, effective as of the 2026 Annual Meeting. Sir Martin E. Franklin commented, "Element Solutions is in a great position and I have absolute faith in this management team and in my fellow directors

      3/23/26 4:30:00 PM ET
      $ESI
      Major Chemicals
      Industrials

      Hims & Hers Names Kathryn Beiser as Chief Communications Officer

      The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

      3/10/26 8:08:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

      Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

      Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

      2/19/26 6:00:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care

      $ACLS
      $CLSK
      $ENVX
      $ESI
      Financials

      Live finance-specific insights

      View All

      Wiley Announces Quarterly Dividend; Allocated $126 million to Dividends and Repurchases in 9 Months of Fiscal 2026

      Wiley (NYSE:WLY), a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning, today announced that its Board of Directors has declared a quarterly cash dividend of $0.355 per share on its Class A and Class B Common Stock, payable on April 23, 2026, to shareholders of record on April 7, 2026. The quarterly dividend is equivalent to an annual dividend of $1.42 per share, an increase from $1.41 per share in Fiscal 2025. In June 2025, Wiley raised its dividend for the 32nd consecutive year. Earlier this fiscal year, Wiley announced that it was increasing its Fiscal 2026 share repurchase allocation to $100 million, u

      3/26/26 7:30:00 AM ET
      $WLY
      $WLYB
      Books
      Consumer Discretionary

      Korn Ferry Announces Third Quarter Fiscal 2026 Results of Operations

      Highlights Korn Ferry reports Q3 FY'26 fee revenue of $717.4 million, an increase of 7% year-over-year with growth in all solutions. Net income attributable to Korn Ferry increased 12% year-over-year, with a margin of 9.1%. Adjusted EBITDA increased 8% year-over-year, with a margin of 17.2%. Diluted and adjusted diluted earnings per share were up 12% and 8% year-over-year, respectively. Estimated remaining fees under existing contracts at the end of the third quarter was $1.9 billion, up 11% year-over-year, led by Digital +16%, Consulting +12% and RPO +10%. Korn Ferry (NYSE:KFY), a global consulting firm, today announced third quarter fee revenue of $717.4 million. In addi

      3/9/26 6:45:00 AM ET
      $KFY
      Diversified Commercial Services
      Consumer Discretionary

      Korn Ferry Board Authorizes Quarterly Dividend Increase for Sixth Consecutive Year

      Dividend Increases 15% to $0.55 Per Share Korn Ferry (NYSE:KFY), a global consulting firm, today announced its Board of Directors has approved a 15% increase in its quarterly cash dividend, raising the quarterly dividend from $0.48 per share to $0.55 per share. This dividend will be payable on April 15, 2026 to shareholders of record on March 27, 2026. This represents an indicated annual dividend of $2.20 per share. "We are pleased to announce a 15 percent per share increase to our quarterly dividend, bringing it to $0.55," said Gary D. Burnison, CEO, Korn Ferry. "This marks our sixth consecutive year of dividend growth. Our ability to consistently return capital to shareholders undersc

      3/5/26 1:23:00 PM ET
      $KFY
      Diversified Commercial Services
      Consumer Discretionary

      $ACLS
      $CLSK
      $ENVX
      $ESI
      Large Ownership Changes

      This live feed shows all institutional transactions in real time.

      View All

      Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

      SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

      11/14/24 5:46:11 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

      Amendment: SEC Form SC 13G/A filed by Element Solutions Inc.

      SC 13G/A - Element Solutions Inc (0001590714) (Subject)

      11/14/24 1:28:32 PM ET
      $ESI
      Major Chemicals
      Industrials

      Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

      SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

      11/14/24 1:22:38 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care